The proposed clinical classification for pituitary adenomas aims to stratify patients based on long-term prognosis and guide individualized management and therapy decisions. It incorporates nine risk factors to assess prognosis, including tumor phenotype, secretory status, and hypopituitarism. While the classification system shows promise in improving patient outcomes, it has limitations, such as the exclusion of critical comorbidities and the need for validation in independent studies. Overall, the framework offers a standardized approach to patient care and research in the field of pituitary adenomas.